BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

Biotechs on STAR suffer amid broader sell-off  As concerns about the COVID-19 outbreak and a mixed recovery outlook rattled stocks traded in Shanghai, biotech stocks on the STAR exchange generally fared worse than the Shanghai...
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout  Evive Biotech Inc. said efbemalenograstim alfa met the primary and secondary endpoints in a Phase III study to prevent chemotherapy-induced neutropenia in breast cancer...
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | Apr 23, 2020
Product Development

BioCentury expands COVID-19 gateway to connect biotechs, researchers with COVID R&D consortium members

BioCentury has expanded the reach of its COVID-19 Resource Center to enable companies and researchers to submit details of investigational products directly to the pharma companies collaborating within the COVID R&D consortium. The consortium, comprising...
BioCentury | Apr 18, 2020
Product Development

Collaborating to clobber COVID-19

An overlapping set of collaborations is focusing the combined intellectual, logistic and economic resources of the life sciences industry, government, academia and non-profits against SARS-Cov2, the virus that causes COVID-19. The latest and broadest collaboration...
BioCentury | Apr 16, 2020
Deals

COVID R&D: Pharmas align behind crowdsourcing solution

Within under a month, a group that started as a mash-up of research heads has morphed into an organized and streamlined collaboration among top pharmaceutical company R&D leaders. Its simple name: COVID R&D. Its goal:...
BioCentury | Mar 27, 2020
Product Development

Pharmas to share assets in COVID-19 consortium led by Narasimhan, Gates

Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation. Novartis AG (NYSE:NVS;...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...
Items per page:
1 - 10 of 1885